Emerging bacterial and fungal pathogens in healthcare and the threat of drug resistance

INTRODUCTION

The increasing problem posed by drug bacteria and fungi, in healthcare settings is a concern for public health professionals and doctors worldwide.¹ This issue is complex resulting from a combination of evolution, human behavior and healthcare practices these pathogens continually. The overuse or misuse of antimicrobials has made treatable infections more challenging to handle. There are types of pathogens, such, as methicillin Staphylococcus aureus (MRSA) vancomycin resistant Enterococci and strains of Mycobacterium tuberculosis that have developed resistance to multiple drugs.^2,3 MRSA in particular has shifted from being a threat in hospitals to becoming a community concern complicating the treatment of infections that were previously easily managed. Recent studies highlight the adaptability of MRSA through changes that may outpace current treatment strategies. While less discussed publicly fungal pathogens are equally worrisome. Candida auris, a yeast with resistance to drugs is rapidly spreading worldwide and drawing attention due, to its resistance capabilities.^4,5 The rise of this fungus highlights the pressing demand, for treatments to combat fungal infections and better methods for diagnosis. The ability of C. auris to withstand therapies presents difficulties in healthcare environments especially for individuals with weakened immune systems who face potentially life threatening infections.^6,7 This calls for a reassessment of approaches to combat fungal infections and a dedicated focus, on developing treatment options. There are factors contributing to the development of drug resistance.^8,9 The excessive use and misuse of antibiotics in healthcare and agriculture play a role. This widespread usage has accelerated the emergence of strains by creating pressure that favors their survival and spread. Recent research consistently emphasizes the role of antibiotic use in reducing resistance underscoring the importance of using these drugs judiciously in both medical and agricultural settings.^10,11 Another challenge is presented by healthcare associated infections (HAIs). These infections often affect patients, such as those undergoing surgery or receiving long term care. The spread of disease-causing germs, in healthcare settings is often made worse by how infection control measures implemented and the use of devices such, as catheters and ventilators which can create opportunities for germs to enter the body. Despite advancements in infection control measures HAIs persist, indicating a need for improvements in hospital protocols and practices. The global nature of healthcare systems. Travel further complicates efforts to control drug pathogens. Easy movement, across borders facilitates the dissemination of resistance mechanisms The widespread occurrence of this phenomenon highlights the significance of cooperation, in monitoring and responding to control. Reduce the transmission of drug resistant pathogens. The financial and healthcare challenges posed by infections that're resistant, to treatment are considerable. Continue to increase. Patients who suffer from these infections often have hospital stays require advanced and expensive treatments and face a greater risk of negative outcomes. This situation leads to increased healthcare expenses. Puts pressure on healthcare systems highlighting the economic consequences of antimicrobial resistance. In response health organizations and researchers advocate for an approach to combat the growing threat of drug pathogens. This approach includes promoting use of antimicrobials, developing antibiotics and antifungals improving diagnostic tools for quick identification of resistant strains and enhancing infection control practices in healthcare settings. The world health organization (WHO) and other public health entities stress the need, for cooperation to tackle this issue effectively. Furthermore, the idea of one health has been gaining momentum as it acknowledges the interdependence, between animal and environmental well-being. It calls for efforts across sectors and disciplines to holistically address antimicrobial resistance. Therefore, the rise of drug fungal pathogens in healthcare presents an ongoing and intricate challenge that necessitates a coordinated multidisciplinary response.^12,13 This problem demands management of existing agents. Addressing this issue effectively is crucial for the future of healthcare and public health emphasizing the necessity, for endeavors worldwide. The main objective of this review is to present insights, into the rise of pathogens in the healthcare sector and the potential challenges they bring particularly, in terms of developing drug resistance.

LITERATURE RESEARCH

This review of literature conducted on November 21st 2023 utilized resources such, as web of science and Google Scholar. To find studies a combination of medical subject headings and keywords like " pathogens " "fungal infections," "drug resistance," and "healthcare challenges" were employed. The primary focus of this review was on studies involving subjects that have been published in English since 2008. The aim was to gain insights, into the changing landscape of healthcare associated infections and the growing concern surrounding drug resistance.

DISCUSSION

Managing the emergence of fungal pathogens, in healthcare is a task. It is crucial to practice use as part of antimicrobial stewardship to combat drug resistance.¹⁴ Utilizing tests allows for personalized treatment while implementing infection control measures helps prevent transmission. To address the evolving resistance personalized treatment plans and innovative therapies are employed.^15,16 Education and surveillance play roles in this process. Collaboration on a scale is essential in the changing landscape of healthcare. Continuous research and innovation are key to staying of resistance mechanisms. The clinical manifestations of drug infections, such as increased severity, treatment failures, complications and limited options emphasize the need for management, with urgency.

Clinical manifestation

The emergence of fungal pathogens, in healthcare along with the growing concern of drug resistance poses an urgent challenge for healthcare providers. These pathogens cause a range of symptoms and conditions often resulting in consequences for patients.^14,17 One significant clinical manifestation of drug bacteria and fungi is the increased severity of infections. Patients affected by these strains often suffer from severe and prolonged illnesses. For instance, infections resulting from the use of methicillin Staphylococcus aureus (MRSA) can cause abscesses that penetrate infections of the skin and soft tissues and sepsis that poses a threat, to life. Similarly, drug-resistant fungal infections like Candida auris progress and are associated with high mortality rates.¹⁸ As these pathogens continue to evolve, managing the presentation of their infections becomes increasingly challenging. Another disconcerting clinical manifestation is the failure of treatments. Patients who previously responded well to antibiotics or antifungals may now find these therapies ineffective. This results in hospital stays higher healthcare costs and frustration for both patients and healthcare providers alike. Treatment failures are a concern, especially when it comes to multidrug tuberculosis (MDR TB). Patients have to endure challenging treatment plans without any assurance of success. The possibility of treatment failure in infections highlights the need for immediate action, against drug resistance.

Complications and co-infections

The presence of drug pathogens increases the chances of complications and co infections which makes it more challenging for doctors to diagnose and treat patients.¹⁹ For instance, individuals, with drug tract infections may experience sepsis or kidney damage if the infection is not effectively managed. In healthcare facilities patients who already have underlying illnesses or have undergone procedures are particularly vulnerable to complications when they encounter drug resistant pathogens. This heightened risk of complications not affects outcomes but also puts additional pressure, on healthcare resources.

Chronic infections

Certain clinical presentations involve the development of lasting infections. Patients who are infected with bacteria that're resistant, to drugs may experience persistent infections that are difficult to eliminate. An example of this is seen in individuals with fibrosis who have respiratory infections caused by multidrug-resistant Pseudomonas aeruginosa. These persistent infections lead to a decline in lung function requiring treatment plans and significantly impacting the patients well-being. Managing these infections adds complexity to healthcare. Emphasizes the need, for innovative therapeutic approaches.

Limited treatment options

The limited options, for treating drug infections are a concern in the medical field. When standard antibiotics or antifungals don't work healthcare providers have to turn to potentially more toxic treatments that may not always be effective. Unfortunately, these alternative treatments come with side effects. Put a strain on healthcare resources as finding the right balance between effective treatment and potential risks is challenging. The lack of treatment options remains an issue in managing drug resistant infections clinically. One of the concerning aspects related to drug pathogens is their ability to spread within healthcare settings leading to outbreaks, in hospitals or long term care facilities. These outbreaks increase sickness and death rates putting pressure on healthcare resources. To control and prevent transmission healthcare providers must implement infection control measures. It becomes clear that robust infection prevention strategies are necessary when faced with these challenges. Ultimately the presence of drug pathogens often results in mortality rates among patients individuals suffering from these pathogens encounter an increased likelihood of mortality owing to the difficulties involved in treating infections. Infections that were previously controllable can escalate into life threatening situations for individuals, with weakened systems who are more susceptible. The consequences of mortality rates extend beyond the affected patients and have a broader impact, on the healthcare system as a whole.

Diagnostic challenges

The accurate and timely diagnosis of infections that're resistant, to drugs is crucial in the field. Healthcare providers face difficulties in identifying the causes of these infections and understanding their patterns of resistance. If drug resistant infections are not diagnosed promptly it can result in delayed treatment initiation leading to outcomes for patients. To effectively address the effects of drug resistance it is essential to have reliable diagnostic tools available. The emergence of fungal pathogens along with the threat of drug resistance presents a challenge for healthcare professionals. This challenge involves infections, treatment failures, complications, long term illnesses, limited treatment options, transmission within healthcare settings, higher mortality rates and complicated diagnostic procedures. These clinical challenges highlight the need, for an approach that includes infection control measures programs promoting appropriate use of antimicrobial medications the development of innovative treatments and international collaboration to mitigate the widespread impact drug resistant pathogens have on healthcare systems and patient well-being.

Management

Managing the rise of fungal infections, in healthcare along with the looming problem of drug resistance is a complex and crucial aspect of modern healthcare delivery. Successfully addressing these challenges requires an approach that covers aspects of clinical management. At the heart of this management lies stewardship a strategy aimed at optimizing the use of antimicrobial agents.²⁰ Strong antimicrobial stewardship programs play a role in promoting careful utilization of antibiotics and antifungals. Their main goal is to decrease the utilization and abuse of these substances as they have an impact, on the development of drug resistance. By implementing stewardship initiatives healthcare facilities can preserve the effectiveness of existing antimicrobials while minimizing the emergence of resistance. Swift and accurate diagnosis is essential for managing drug pathogens in clinical settings.^21,22 The introduction of tools has transformed this field. Molecular tests such, as PCR and NGS provide outcomes that enable healthcare professionals to tailor treatment strategies according to the pathogens and their resistance patterns. These advanced diagnostic methods are invaluable in combating drug resistance by enabling prompt and targeted interventions. In healthcare settings stringent isolation measures and infection control protocols are essential, for containing the spread of drug pathogens. Patients who are infected or carrying drug strains of pathogens are placed under precautions to prevent the transmission of these resistant strains. Depending on how the pathogen spreads this can involve contact precautions, droplet precautions or airborne precautions. These precautionary measures are crucial, in stopping the spread of infections within healthcare settings. When it comes to treating patients with drug infections a personalized approach is necessary. This involves tailoring treatment regimens based on the pathogen and its resistance profile. Collaboration between disease specialists, microbiologists and pharmacists is often required to develop these tailored treatment plans. For example, in cases of multidrug tuberculosis (MDR TB) treatment regimens need to be customized based on susceptibility testing results. Similarly, when dealing with infections where drug resistance's a growing concern, selecting the appropriate antifungal therapy requires careful consideration of resistance patterns and host factors. The days of using a one size fits all approach in treatment have given way, to personalized strategies. To combat the increasing problem of drug resistance there is research and development focused on discovering antibiotics and antifungals that work through unique mechanisms of action. Using a combination of drugs simultaneously known as combination therapy holds potential, in enhancing the effectiveness of treatment while minimizing the chances of developing resistance. Novel treatments, like immunotherapies and phage therapy are being recognized for their potential in managing drug infections. These innovative approaches play a role in the fight against drug resistance. It's important to note that effective clinical management involves more than treatment-it also encompasses education and training, in infection prevention and control. Healthcare professionals undergo education to understand the risks associated with drug pathogens and learn how to prevent their spread. The educational programs cover topics such, as practicing hand hygiene using personal protective equipment correctly maintaining a clean environment and following infection control protocols strictly.²³ It is equally crucial to educate patients and their families so they can actively contribute to reducing healthcare associated infections. Monitoring and studying the prevalence of drug pathogens among patients is a part of clinical management. This includes testing patients for these pathogens those at high risk and analyzing their genetic makeup to understand how they are spreading. Epidemiological investigations help identify the source of outbreaks. Guide infection control efforts. Additionally, regional and national surveillance networks are essential in monitoring the movement of drug strains across borders and coordinating responses during outbreaks. International collaboration is critically important due to the nature of healthcare and travel. Continuous research drives improvements, in management by evaluating treatment effectiveness understanding drug resistance mechanisms, developing diagnostics and advancing infection control strategies. Clinical trials are performed to evaluate the effectiveness of treatments, diagnostic instruments and measures to control infections. Having a knowledge of the factors that contribute to drug resistance is crucial, for creating interventions. Healthcare providers constantly improve their clinical management strategies by staying up, to date with the advancements. On the other hand, effectively managing emerging bacterial and fungal pathogens, in healthcare settings despite the concerning issue of drug resistance calls for a thorough and diverse approach. This approach includes practices such as use of antimicrobials, prompt and accurate diagnostics, strict infection control measures, personalized treatment plans, innovative therapeutic methods, education initiatives, surveillance and epidemiology activities well, as international collaboration. By addressing all these aspects comprehensively healthcare providers can be better prepared to tackle the challenges presented by drug pathogens. Ultimately this will help protect outcomes and promote health.

CONCLUSION

The management of emerging fungal diseases, in healthcare considering the growing concern of drug resistance requires an approach. Antimicrobial stewardship serves as the basis emphasizing use of antibiotics. Quick diagnostic methods improve accuracy while strict infection control measures prevent spread. Customized treatment plans and innovative therapies adapt to changing resistance patterns. Education and surveillance strengthen prevention efforts and global collaboration is crucial in our interconnected world. Research and innovation propel advancements in this field. The various clinical presentations ranging from increased severity, to treatment options underscore the importance of an approach. It is essential to address this multifaceted challenge in order to protect well-being and public health.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

1. 1. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109:309-18.
2. 2. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pt. 2015;40:277-83.
3. 3. Terreni M, Taccani M, Pregnolato M. New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives. Molecules. 2021;26(9).
4. 4. Ademe M, Girma F. Candida auris: From Multidrug Resistance to Pan-Resistant Strains. Infect Drug Resist. 2020;13:1287-94.
5. 5. Chakrabarti A, Sood P. On the emergence, spread and resistance of Candida auris: host, pathogen and environmental tipping points. J Med Microbiol. 2021;70(3).
6. 6. Egger NB, Kainz K, Schulze A, Bauer MA, Madeo F, Carmona-Gutierrez D. The rise of Candida auris: from unique traits to co-infection potential. Microb Cell. 2022;9:141-4.
7. 7. Ahmad S, Alfouzan W. Candida auris: Epidemiology, Diagnosis, Pathogenesis, Antifungal Susceptibility, and Infection Control Measures to Combat the Spread of Infections in Healthcare Facilities. Microorganisms. 2021;9(4).
8. 8. Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK. Overcoming antifungal resistance. Drug Discov Today Technol. 2014;11:65-71.
9. 9. Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS. Mechanisms of Antifungal Drug Resistance. Cold Spring Harb Perspect Med. 2014;5:a019752.
10. 10. Beceiro A, Tomás M, Bou G. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? Clin Microbiol Rev. 2013;26:185-230.
11. 11. Ayukekbong JA, Ntemgwa M, Atabe AN. The threat of antimicrobial resistance in developing countries: causes and control strategies. Antimicrobial Resistance Infect Control. 2017;6:47.
12. 12. Arastehfar A, Gabaldón T, Garcia-Rubio R, Jeffrey DJ, Martin H, Helmut JFS, et al. Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium. Antibiotics (Basel). 2020;9:877.
13. 13. Vitiello A, Ferrara F, Boccellino M, Annarita P, Carla C, Emilio C, et al. Antifungal Drug Resistance: An Emergent Health Threat. Biomedicines. 2023;11:1063.
14. 14. Fisher MC, Alastruey-Izquierdo A, Berman J, Tihana B, Elaine MB, Paul B, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol. 2022;20:557-71.
15. 15. Harun MGD, Anwar MMU, Sumon SA, Zakiul MH, Tahrima MM, Aninda R, et al. Rationale and guidance for strengthening infection prevention and control measures and antimicrobial stewardship programs in Bangladesh: a study protocol. BMC Health Serv Res. 2022;22:1239.
16. 16. Barrera-Cancedda AE, Riman KA, Shinnick JE, Buttenheim AM. Implementation strategies for infection prevention and control promotion for nurses in Sub-Saharan Africa: a systematic review. Implement Sci. 2019;14:111.
17. 17. Garvey M, Meade E, Rowan NJ. Effectiveness of front line and emerging fungal disease prevention and control interventions and opportunities to address appropriate eco-sustainable solutions. Sci Total Environment. 2022;851:158284.
18. 18. Gómez-Gaviria M, Martínez-Álvarez JA, Chávez-Santiago JO, Mora-Montes HM. Candida haemulonii Complex and Candida auris: Biology, Virulence Factors, Immune Response, and Multidrug Resistance. Infect Drug Resist. 2023;16:1455-70.
19. 19. Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol. 2018;4:482-501.
20. 20. Kakkar AK, Shafiq N, Singh G, Pallab R, Vikas G, Ritesh A, et al. Antimicrobial Stewardship Programs in Resource Constrained Environments: Understanding and Addressing the Need of the Systems. Front Public Health. 2020;8:140.
21. 21. Majumder MAA, Rahman S, Cohall D, Ambadasu B, Keerti S, Mainul H et al. Antimicrobial Stewardship: Fighting Antimicrobial Resistance and Protecting Global Public Health. Infect Drug Resist. 2020;13:4713-38.
22. 22. Infectious Diseases Society of A. Combating Antimicrobial Resistance: Policy Recommendations to Save Lives. Clin Infect Dis. 2011;52:S397-428.
23. 23. Haque M, Sartelli M, McKimm J, Abu Bakar M. Health care-associated infections - an overview. Infect Drug Resist. 2018;11:2321-33.